The lawsuit accuses Gilead of delaying generic Truvada versions through “extensive and unlawful anti-competitive schemes,” particularly “collusive licensing agreements” with potential rivals. It was filed in the Chancery Court by two shareholders.
The plaintiffs also say they want to investigate claims—raised in a patent infringement suit filed by the federal government—that Gilead is wrongly profiting off of certain government patents without sharing ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.